A Phase I Dose Escalation Study with Anti-CD44v6 Bivatuzumab Mertansine in Patients with Incurable Squamous Cell Carcinoma of the Head and Neck or Esophagus A Phase I Dose Escalation Study with Anti-CD44v6 Bivatuzumab Mertansine in Patients with Incurable

  • Tijink B
  • Buter J
  • Bree R
 et al. 
  • 2

    Readers

    Mendeley users who have this article in their library.
  • N/A

    Citations

    Citations of this article.

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document

Authors

  • Bernard M Tijink

  • Jan Buter

  • Remco De Bree

  • Alexander Staab

  • C Rene

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free